Patent US4676974A successfully refreshed from Google Patents.
US4676974A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Breath test for pancreatic exocrine function
Assignee: University of California
•
Filing: 1984-05-17
•
Granted: 1987-06-30
•
Expires: 2004-05-17
Abstract
Abstract Pancreatic exocrine function is determined by a breath test method wherein a radioactive labelled ester such as cholesterol octanoate is ingested in the body and is hydrolyzed by pancreatic enzymes and oxidized to labelled Co 2 which is expired in the breath. The rate of appearance of labelled Co 2 in the breadth is a function of the rate of hydrolysis by pancreatic enzymes which in turn reflects pancreatic exocrine function. Before ingestion, the ester is mixed with a carrier substrate such as a triglyceride to form a lipid matrix containing the ester and the lipid matrix is suspended in aqueous solution. To insure that low levels of expired labelled Co 2 is due to pancreatic exocrine insufficiency, the ester is ingested simultaneously with a differentially labelled unesterfied carboxylic acid or the test method is repeated with an added step of simultaneously ingesting the ester with exogenously provided pancreatic enzymes.
Inventors
- 👤 Alan F. Hofmann
- 👤 Stephen G. Cole
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 23:32
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1206; A61K2123/00; Y; Y10; Y10S; Y10S436/00; Y10S436/90; Y10T; Y10T436/00; Y10T436/13
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
116 words
A method for determining pancreatic exocrine function in a patient's body comprising the patient ingesting an ester R2COOR1 where R1 is a sterol group, and R2 is a traceable hydrocarbon group oxidizable to traceable carbon dioxide in the body, said traceable carbon dioxide being expired from the body in the breath, and detecting the rate of appearance of said traceable carbon dioxide in the breath of said patient and comparing the rate of appearance of said traceable carbon dioxide produced when said ester is ingested alone with the rate of traceable carbon dioxide produced when said ester is ingested with exogenously added pancreatic enzymes suitable for hydrolyzing said ester as an indication of pancreatic exocrine function.
Claim 2
Independent Claim
116 words
A method for determining pancreatic exocrine function in a patient's body comprising the patient ingesting an ester R2COOR1 where R1 is a sterol group, and R2 is a traceable hydrocarbon group oxidizable to traceable carbon dioxide in the body, said traceable carbon dioxide being expired from the body in the breath, and detecting the rate of appearance of said traceable carbon dioxide in the breath of said patient and comparing the rate of appearance of said traceable carbon dioxide produced when said ester is ingested alone with the rate of traceable carbon dioxide produced when said ester is ingested with exogenously added pancreatic enzymes suitable for hydrolyzing said ester as an indication of pancreatic exocrine function.
Claim 3
Dependent Claim
19 words
A method according to claim 1 wherein said R2 traceable hydrocarbon group comprises from 2 to 10 carbon atoms.
Claim 4
Dependent Claim
25 words
A method according to claim 2 wherein said traceable R2 hydrocarbon group comprises one or more carbon atoms of either 14 C or 13 C.
Claim 5
Dependent Claim
46 words
A method according to claim 3 wherein the ester is prepared for patient injestion by combining said ester with a triglyceride in solution and agitating said solution forming a lipid matrix of triglyceride situated about said ester and suspending said lipid matrix in an aqueous solution.
Claim 6
Independent Claim
95 words
A method for determing pancreatic exocrine function in a patient's body comprising the patient ingesting simultaneously an ester R2COOR1, and a salt of a fatty acid R3COOH, wherein R1 is a sterol group, and R2 and R3 are differentially traceable groups oxidizable to differentially traceable carbon dioxides in the body, said differentially traceable carbon dioxides being expired from said body in the breath and detecting said differentially traceable carbon dioxides in the breath of said patient, and comparing the rates of appearance of said differentially traceable carbon dioxides as an indication of pancreatic exocrine function.
Claim 7
Independent Claim
95 words
A method for determing pancreatic exocrine function in a patient's body comprising the patient ingesting simultaneously an ester R2COOR1, and a salt of a fatty acid R3COOH, wherein R1 is a sterol group, and R2 and R3 are differentially traceable groups oxidizable to differentially traceable carbon dioxides in the body, said differentially traceable carbon dioxides being expired from said body in the breath and detecting said differentially traceable carbon dioxides in the breath of said patient, and comparing the rates of appearance of said differentially traceable carbon dioxides as an indication of pancreatic exocrine function.
Claim 8
Dependent Claim
31 words
A method according to claim 5 wherein said R2 group comprises from 2 to 10 carbon atoms and one or more of said carbon atoms is 14 C or 13 C.
Claim 9
Dependent Claim
31 words
A method according to claim 6 wherein R3 comprises from 2 to 10 carbon atoms and one or more of said carbon atoms is labelled with 14 C or 13 C.
Claim 10
Dependent Claim
10 words
A method according to claim 7 wherein R1 is cholesterol.
Claim 11
Dependent Claim
12 words
A method according to claim 8 wherein said ester is cholesterol octanoate.
Claim 12
Dependent Claim
17 words
A method according to claim 9 wherein said salt of said fatty acid is an octanoate salt.
Claim 13
Dependent Claim
64 words
A method according to claim 8 wherein said ester, and said salt of said fatty acid are prepared for patient ingestion by combining said ester and said fatty acid salt with a triglyceride in solution, and agitating said solution thereby forming a lipid matrix of said triglyceride situated about said ester and fatty acid salt and suspending said lipid matrix in an aqueous solution.
Claim 14
Dependent Claim
62 words
A composition useful for determining pancreatic exocrine function prepared by combining in aqueous solution a triglyceride, cholesterol octanoate, and an octanoate salt, and agitating said solution to form a lipid matrix, said lipid matrix comprising said triglyceride, cholesterol octanoate, and octanoate salt, and said cholesterol octanoate and octanoate salt exhibiting one or more different traceable isotopes of carbon detectable as carbon dioxide.
Claim 15
Dependent Claim
62 words
A composition useful for determining pancreatic exocrine function prepared by combining in aqueous solution a triglyceride, cholesterol octanoate, and an octanoate salt, and agitating said solution to form a lipid matrix, said lipid matrix comprising said triglyceride, cholesterol octanoate, and octanoate salt, and said cholesterol octanoate and octanoate salt exhibiting one or more different traceable isotopes of carbon detectable as carbon dioxide.
References Cited (Backward Citations)
US3844894A
Cited
US3917812A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-06-29 | 1990-12-29 | 1991-06-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-06-29 | 1994-12-29 | 1995-06-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-06-29 | 1998-12-29 | 1999-06-30 | $7700.00 | Window Closed / Lapsed |